Translating transcriptomics analysis into diagnostic workflows: clinical variant identification and interpretation in...

Despite significant advancements in genetic diagnosis, there are still bottlenecks in DNA-level testing. Challenges to diagnosis include the inability to identify the causal variant, and the lack of functional evidence leading to an accumulation of variants of uncertain significance (VUS). Recently, there has been growing evidence demonstrating the diagnostic value of RNA sequencing (RNA-seq).

This diagnostic study implemented RNA-seq analysis of blood (and fibroblasts, if available) in 102 patients with genetically undiagnosed diseases. An outlier analysis for gene expression and splicing was adopted through a multi-modal machine learning algorithm (i.e., Detection of RNA Outliers Pipeline-DROP).

Our analysis aided the interpretation of 22/102 (21.6%) patients through both hypothesis-driven (i.e., with a prior genetic candidate; n = 10) and hypothesis-free (i.e., without a prior genetic candidate; n = 12) approaches. Not only did this workflow aid genetic diagnosis (n = 12), but it also provided additional information to known findings (n = 4) and guided the discovery of unestablished disease mechanisms (n = 6).

This study demonstrated the clinical and scientific value of blood transcriptomics through both hypothesis-driven and hypothesis-free approaches. We have proposed an initial framework for RNA-seq implementation into the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) guidelines using PVS1 (null variants) and PP4 (phenotypic specificity). However, other considerations are required, including further clarifications for thresholds, and detailed guidance on the incorporation of different aspects of RNA-seq results (e.g., degree of nonsense-mediated decay and completeness of splicing).

This study was supported by grants from the Society for the Relief of Disabled Children, the Health and Medical Research Fund (HMRF) and Commissioned Paediatric Research at HKCH under HMRF both by the Health Bureau, The Government of the Hong Kong Special Administrative Region.